Latest Headlines

Latest Headlines

Xarelto tees up big new European approval

Bayer's ($BAY) new anticoagulant drug Xarelto won a crucial recommendation for European approval for the prevention of stroke in patients with atrial fibrillation. The drug was already approved to

Bayer scores encore for blood-thinner Xarelto in Europe

Bayer ($BAYN) and Johnson & Johnson's ($JNJ) Xarelto has notched another victory this month. European regulators have backed the potential blockbuster blood-thinner drug for approval to prevent

Report: Bayer could sell key Alzheimer's-detecting drug

Amid the upheaval of Bayer's planned restructuring is speculation that the German drugmaker could divest its experimental drug florbetaben, which is intended to home in on an Alzheimer's marker for

Abbott, Roche, Novartis top Big Pharmas for workers

Science magazine put Big Pharma firms Abbott Laboratories ($ABT), Novartis ($NVS), Roche, Eli Lilly ($LLY), AstraZeneca ($AZN) and Bayer on its list of the best biopharma employers. But none of the

J&J's blockbuster hopeful Xarelto bounces back with AdComm backing

The blood thinner Xarelto came through an FDA advisory committee meeting looking better than some had expected. The AdComm backed approval of the potential blockbuster for preventing stokes in

Deal-minded analysts eye Bayer, AZ for M&A

As the FDA's expert advisors debate the future of the Bayer-Johnson & Johnson ($JNJ) bloodthinner Xarelto, market-watchers are playing matchmaker. Bayer's stock went reeling after FDA blasted the

FDA review drops a bombshell on Bayer, J&J anti-clotting drug Xarelto

The FDA dropped a bombshell on the anti-clotting drug Xarelto (rivaroxaban) this morning, noting in an agency review that Bayer ($BAYN) and Johnson & Johnson ($JNJ) had offered insufficient data

Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful

Bayer and its biotech partner Algeta took a big step today toward a relatively quick FDA decision on their closely-watched prostate cancer drug Alpharadin (radium-223 chloride). Regulators are

NEJM: Xarelto at least equal to warfarin

Bayer's new anti-clotting drug may not be superior to the old standby, warfarin, a new journal article suggests. But it is certainly just as good. And as co-author Gregory Zoppo told Reuters,

Bayer mulls bid for Pfizer's vet unit

Bayer CEO Marijn Dekkers says he's taking a look at bidding on Pfizer's ($PFE) animal health unit if the company decides to put it up for auction. The company is most interested in "smaller" deals